



# 11



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

1 September 2003

Patents Act 1977  
(Rule 16)



# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

08JUL98 E374017-6 D02882  
F01/7700 25.00 - 9814717.6 The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference **TAB/NT/50088/001**

2. Patent application number  
(The Patent Office will fill in this part)

**9814717.6**

07 JUL 1998

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)

**BESPAK plc  
BERGEN WAY  
NORTH LYNN INDUSTRIAL ESTATE  
KING'S LYNN  
NORFOLK, PE30 2JJ  
UNITED KINGDOM**

Patents ADP number (*if you know it*)

If the applicant is a corporate body, give the country/state of its incorporation

**UNITED KINGDOM**

4372345001

4. Title of the invention

**IMPROVEMENTS IN DRUG DELIVERY DEVICES**

5. Name of your agent (*if you have one*)

**BOULT WADE TENNANT  
27 FURNIVAL STREET  
LONDON  
EC4A 1PQ**

"Address for service" in the United Kingdom to which all correspondence should be sent (*including the postcode*)

Patents ADP number (*if you know it*)

**42001**

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country

Priority application number  
(*if you know it*)

Date of filing  
(*day/month/year*)

**U.K.  
U.K.**

**9803780.7  
9808804.0**

**23 FEBRUARY 1998  
24 APRIL 1998**

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(*day / month / year*)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request?

**YES**

(Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

# Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

## Continuation sheets of this form

Description 8  
Claim(s) 3  
Abstract 0  
Drawing(s) 2 + 2

10. If you are also filing any of the following, state how many against each item.

## Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77) 1

Request for substantive examination (Patents Form 10/77) 1

Any other documents  
(Please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

7 July 1998

12. Name and daytime telephone number of person to contact in the United Kingdom MRS. T. A. BUCKS  
0171 404 5921

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

IMPROVEMENTS IN DRUG DELIVERY DEVICES

5 This invention relates to improvements in drug delivery devices and particularly those for dispensing a metered dose of a medicament.

10 In metered dose inhalers, an aerosol stream from a pressurised dispensing container is fired towards a patient or user of the inhaler into an air flow. The air flow is created by a user inhaling through a mouthpiece of the inhaler and the medicament is released into this air flow at a point between the air inlet holes and the mouthpiece.

15 Conventional metering valves for use with pressurised dispensing containers comprise a valve stem coaxially slidable within a valve member defining an annular metering chamber, and outer and inner annular seals operative between the respective outer and inner ends of the valve stem and the valve member to seal the metering chamber therebetween. The valve stem is hollow whereby in a non-dispensing position of the valve stem, the metering chamber is connected to the container and charged with product therefrom. The valve stem is movable against the action of a spring to a dispensing position wherein the metering chamber is isolated from the container and vented to atmosphere for the discharge of product.

25 Other drug delivery devices include apparatus in which capsules containing a powdered medicament are mechanically opened at a dispensing station where inhaled air subsequently entrains the powder, which is then dispensed through a mouthpiece.

30 A problem with all such drug delivery devices is that deposition of the medicament, or a solid component from a suspension of a particulate product in a liquid propellant, on the internal surfaces and

35

other components of the devices occurs after a number of operation cycles and/or storage. This can lead to reduced efficiency of operation of the device and of the resulting treatment in that deposition of the product reduces the amount of active drug available to be dispensed.

Some prior art devices rely on the dispenser being shaken in an attempt to dislodge the deposited particles as a result of the movement of a liquid propellant and product mixture. However, whilst this remedy is effective within the body of the container itself, it is not effective for particles deposited on the inner surfaces of the metering chamber. As the size of the chamber is significantly smaller, the restricted flow of fluid in the metering chamber (caused by the tortuosity of the flow path through the chamber) means that the fluid in the metering chamber does not move with enough energy to adequately remove the deposited particles.

One solution is proposed in our pending application GB 9721684.0 in which a liner of a material such as fluoropolymer, ceramic or glass is included to line a portion of the wall of a metering chamber in a metering valve. Although this solves the problem of deposition in these types of dispensers, it does require the re-design or modification of moldings and mould tools for producing the valve members to allow for the insertion of the liner.

It is an object of the present invention to provide drug delivery devices in general in which the deposition of the product and active drug component is minimised.

According to the invention there is provided apparatus for dispensing a medicament, wherein at least a portion of one or more of the internal

surfaces of components of the apparatus which come into contact with medicament during storage or dispensing has a layer of one or more cold plasma polymerised monomers bonded to at least a portion thereof.

A particular embodiment of the present invention will now be described, by way of example only, with reference to the accompanying drawings in which;

Fig. 1 is a cross-sectional view through an inhaler, which is one type of drug delivery device of the present invention; and

Fig. 2 is a cross sectional view of a metering valve used in another type of drug delivery device.

In Fig. 1 an inhaler 10 for a product such as a medicament comprises a housing 11 for receiving a pressurised dispensing container 12 of a medicament and a mouthpiece 14 for insertion into the mouth of a user of the inhaler 10.

The container housing 11 is generally cylindrical and open at its upper end. A lower wall 15 of the housing 11 includes an annular socket 16 for receiving the tubular valve stem 17 of the container 12. The socket 16 communicates via a duct 18 ending in an orifice 19 with the mouthpiece 14. The lower wall 15 also has holes 20 for allowing air to flow through the container housing 11 into the mouthpiece 14.

The mouthpiece 14 may be generally circular or shaped to fit the mouth and is connected to or forms a part of the housing 11.

In use, a patient or user holds the inhaler 10, usually in one hand, and applies his mouth to the mouthpiece 14. The user then inhales through the

mouthpiece 14 and this creates an airflow through the cylindrical housing 11, from its open end around the dispensing container 12, through the holes 20 and into the mouthpiece 14. After the user has started  
5 inhaling through the mouthpiece 14, the container 12 is depressed downwardly onto its stem 17 to release a dose of medicament from the container 12. The dose of medicament is projected by the pressure in the container 12 via the duct 18 and through the orifice  
10 19. It then mixes with the airflow through the mouthpiece 14 and is hence inhaled by the user.

In traditional inhalers, all of the components are plastic mouldings, which gives rise to the deposition problems described above. The particular  
15 problem areas in devices such as inhalers are the internal surfaces 21 of the mouthpiece 14, the internal surfaces 22 of the duct 18 and the walls 23 defining the orifice 19. In some inhalers 10, the diameter of at least a part of the duct 18 can be as  
20 little as 0.5mm and so any deposition on its internal surfaces 22 could lead to not only the problem of a reduction in active drug components being available, but also dispensing difficulties.

The metering valve 110 illustrated in Fig. 2 is  
25 another type of drug delivery device or dispenser, and includes a valve stem 111 which protrudes from and is axially slidable within a valve member 112, the valve member 112 and valve stem 111 defining therebetween an annular metering chamber 113. The valve member 112  
30 is located within a valve body 114 which is positioned in a pressurised container (not shown) containing a product to be dispensed. The metering valve 110 is held in position with respect to the container by means of a ferrule 115 crimped to the top of the  
35 container and sealing being provided between the valve

body 114 and container by an annular gasket 116.

5 An outer seal 117 and an inner seal 118 of an elastomeric material extend radially between the valve stem 111 and the valve member 112. The outer seal 117 is radially compressed between the valve member 112 and valve stem 111 so as to provide positive sealing contact, the compression being achieved by using a seal which provides an interference fit on the valve stem 111 and/or by the crimping of the ferrule 115  
10 onto the pressurised container during assembly.

The valve stem 111 has an end 119 which protrudes from the valve member 112 and ferrule 115 which is a hollow tube and which is closed off by flange 120 which is located within the metering chamber 113. The  
15 hollow end 119 of valve stem 111 includes a discharge port 121 extending radially through the side wall of the valve stem 111. The valve stem 111 further has an intermediate section 122, which is also hollow and defining a central passage and which has a pair of  
20 spaced radial ports 123, 124 which are interconnected through a central cavity.

A spring 125 extends between a second flange 126, separating the intermediate section 122 of the valve stem 111 and an inner end 127 of the valve stem 111,  
25 and an end of the valve body 114 to bias the valve stem 111 in a non-dispensing position in which the first flange 120 is held in sealing contact with the outer seal 117. The second flange 126 is located outside the valve member 112, but within the valve  
30 body 114.

The metering chamber 113 is sealed from the atmosphere by the outer seal 117, and from the pressurised container to which the valve 110 is attached by the inner seal 118. In the illustration  
35 of the valve 110 shown in Fig. 1 radial ports 123, 124

---



together with the central cavity in the intermediate section 122 of the valve member 111 connect the metering chamber 113 with the container so that in this non-dispensing condition the metering member 113  
5 will be charged with product to be dispensed.

Upon depression of the valve stem 111 relative to the valve member 112 so that it moves inwardly into the container, the radial port 124 is closed off as it passes through the inner seal 118, thereby isolating  
10 the metering chamber 113 from the contents of the pressurised container. Upon further movement of the valve stem 111 in the same direction to a dispensing position the discharge port 121 passes through the outer seal 117 into communication with the metering  
15 chamber 113. In this dispensing position the product in the metering chamber 113 is free to be discharged to the atmosphere via the discharge port 121 and the cavity in the hollow end 119 of the valve stem 111.

When the valve stem 111 is released, the biasing  
20 of the return spring 125 causes the valve stem 111 to return to its original position. As a result the metering chamber 113 becomes recharged in readiness for further dispensing operations.

The component parts of conventional drug  
25 dispensing devices, such as valve members, valve stems, inhaler housings and so on, are generally formed as single mouldings from material such as acetal, polyester or nylon which are prone to the deposition problems described above. Although in some  
30 cases it might be possible to include a separate liner of a material such as a fluoropolymer, ceramic or glass to line a portion of the area in which deposition problems occurs, this requires the re-design or modification of mouldings and mould tools so  
35 that the components can accommodate such lines.

---

In the present invention we propose a solution in which the component parts of the drug dispensing devices are made by conventional tooling and moulds from the traditional materials listed above. They are then subjected to a cold plasma polymerisation treatment of one or more monomers which is a "hydrophobic" treatment which creates a very thin layer of the plasma polymer on the surface of the component parts which significantly reduces the deposition of active drugs on the relevant surfaces due to factors such as anti-frictional and waterproof characteristics and low surface energy.

The preferred monomer to use in this process is tetrafluoroethylene (TFE) which would create a thin layer of plasma polymerised TFE on the appropriate surface. Other fluorinated hydrocarbons may also be used, such as trifluoroethylene, vinylidene fluoride and vinyl fluoride. The two monomers fluoroethylene and fluoropropylene may also be used to form the copolymer fluorinated ethylene-propylene (FEP). As a further alternative, siloxanes may be used, such as dimethyl siloxane, to give a layer of plasma polymerised dimethylsiloxane.

The process is known as "cold plasma" treatment as the temperature within the body of the plasma is ambient. Thus thermoplastic materials such as polybutyrene terephthalate (PBT), nylon, acetile and tetrabutylene terephthalate (TBT) can be treated without fear of thermal damage. The treatment is a vacuum procedure in which the components are placed inside a chamber which is evacuated to less than 0.005 Torr. One or more monomers are introduced to the chamber at a controlled rate and a 13.56 MHZ r.f. signal is applied to an external antenna. The plasma is ignited within the chamber and maintained for a

given time at the preselected power setting. At the  
end of the treatment the plasma is extinguished, the  
chamber flushed and the products retrieved. As a  
result a thin layer (for example 0.005 to 0.5 microns)  
5 of the plasma polymerised material is intimately  
bonded to the surface of the component.

Either an entire component within the drug  
delivery device, or just the surfaces of one or more  
component which would come into contact with the  
10 medicament during actuation, could be treated to  
provide an improved drug delivery device according to  
the present invention. In the case of the type of  
inhalers as shown in Fig. 1, surfaces 21, 22 and 23  
may be treated. In a typical dry powder inhaler, the  
15 inner surface of the mouthpiece and any channel  
leading to the mouthpiece from the point of powder  
storage, i.e. from a capsule, bulk storage chamber or  
a pre-metered chamber of a device. In the metering  
valve of Figure 2, the valve member 12 alone may be  
20 treated. However additional benefits can be achieved  
in treating some or all of the other plastic and  
rubber parts of the valve, including the valve body  
114 and the seals 116, 117 and 118. The method can  
also be used to treat components of many other  
25 delivery devices including nasal pumps, non-  
pressurised actuators, foil storage types, breath  
actuated inhaler devices and breath co-ordinating  
devices and so on.

30

35

CLAIMS:

- 5
1. Apparatus for dispensing a medicament wherein at least a portion of one or more of the internal surfaces of components of the apparatus which come into contact with medicament during storage or
- 10 dispensing has a layer of one or more cold plasma polymerised monomers bonded to at least a portion thereof.
2. Apparatus as claimed in claim 1 in which the
- 15 layer is of a cold plasma polymerised fluorinated hydrocarbon.
3. Apparatus as claimed in claim 2 in which the one or more monomers for cold plasma polymerisation are
- 20 selected from the group of materials comprising tetrafluoroethylene, trifluoroethylene, vinylidene fluoride, vinylfluoride, fluoroethylene and fluoropropylene.
- 25 4. Apparatus as claimed in claim 1 in which the layer is of a cold plasma polymerised siloxane.
5. Apparatus as claimed in claim 4 in which the monomer for cold plasma polymerisation is dimethyl
- 30 siloxane.
6. Apparatus as claimed in any one of the preceding claims in which the treated portion is made from a plastic polymer or synthetic rubber.
- 35

7. Apparatus as claimed in any one of the preceding claims in which the apparatus comprises a housing adapted to receive a container for storing the medicament, a mouthpiece and duct means connecting an outlet of the container with the mouthpiece, and at least a portion of one or more of the internal surfaces of the duct and/or mouthpiece is treated.

8. Apparatus as claimed in claim 7 in which at least a portion of the surfaces of the duct and the mouthpiece have a layer of plasma polymer bonded thereto.

9. Apparatus as claimed in any one of claims 1 to 6 in which the apparatus is a metering valve for use with a pressurised dispensing container, the valve comprising a valve stem co-axially slidable within a valve member, said valve member and valve stem defining an annular metering chamber, outer and inner annular seals operative between the respective outer and inner ends of the valve member and the valve stem to seal the annular metering chamber therebetween, wherein at least a portion of the metering valve is treated to have a layer of a plasma polymer bonded to at least a portion of an internal surface of the metering chamber.

10. Apparatus as claimed in claim 9 in which at least a portion of the surface of the valve member has the layer of plasma polymer bonded thereto.

11. Apparatus as claimed in claim 9 or claim 10 in which at least a portion of the surface of the valve stem has the layer of plasma polymer bonded thereto.

12. Apparatus as claimed in any one of claims 9 to 11 in which at least a portion of the surface of the seals have the layer of plasma polymer bonded thereto.

5 13. Apparatus as claimed in any one of claims 9 to 12 in which the valve further comprises a valve body in which the valve member is located, the valve body having the layer of plasma polymer bonded to at least a portion of its surface.

10 14. Apparatus as claimed in any one of claims 9 to 13 further comprising a gasket extending between the sealing surfaces of the metering valve and a pressurised dispensing container, said gasket having  
15 the layer of plasma polymer bonded to at least a portion of the surface thereof.

20 15. Apparatus substantially as hereinbefore described with reference to and as shown in the accompanying drawings.

25

30

35

---

1/2

FIG. 1




FIG. 2

